Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 3,078 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Advanced Stage Solid Tumors Clear all

Conditions: Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric, Leukemia, Lymphocytic, Acute, Adult, Leukemia, Myelocytic, Acute, Pediatric, Leukemia, Myelocytic, Acute, Adult, Myelodysplastic Syndromes, Adult
Interventions: clofarabine (IV formulation); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 2
States / cities: Dallas, Texas • Tyler, Texas

Conditions: Solid Tumour
Interventions: HLX07, Acetaminophen, dexamethasone, diphenhydramine, 5-HT3 inhibitor; Drug
Lead sponsor: Henlix, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Fremont, California

Conditions: Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer
Interventions: CYH33; Drug
Lead sponsor: Haihe Biopharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: New Haven, Connecticut • Dallas, Texas • Houston, Texas

Conditions: Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Melanoma of the Skin, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer
Interventions: Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, TLR8 Agonist VTX-2337; Drug · Other · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Metastatic or Locally Advanced Unresectable Solid Tumors
Interventions: M4112; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: New Haven, Connecticut • Houston, Texas • San Antonio, Texas

Conditions: Solid Tumor, NSCLC
Interventions: JAB-3312, Binimetinib, Pembrolizumab, Sotorasib, Osimertinib; Drug
Lead sponsor: Allist Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 12 more

Conditions: SCLC, Small Cell Cancer, Advanced Solid Tumor, High Grade Neuroendocrine Cancers
Interventions: Lurbinectedin, Berzosertib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing, Talazoparib; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 35
States / cities: Duarte, California • Irvine, California • La Jolla, California + 28 more

Conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma, Ewing Sarcoma, Hepatoblastoma, Langerhans Cell Histiocytosis, Malignant Germ Cell Tumor, Malignant Glioma, Osteosarcoma, Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Rhabdoid Tumor, Rhabdomyosarcoma, Soft Tissue Sarcoma, Wilms Tumor
Interventions: Laboratory Biomarker Analysis, Vemurafenib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 114
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 90 more

Conditions: Neoplasms
Interventions: Paclitaxel, Copanlisib (BAY80-6946); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: St Louis, Missouri • New York, New York • Houston, Texas

Conditions: Solid Tumor, Adult
Interventions: HTI-1066 dose level 1, HTI-1066 dose level 2, HTI-1066 dose level 3, HTI-1066 dose level 4; Drug
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Scottsdale, Arizona • Nashville, Tennessee • Houston, Texas

Conditions: Advanced or Metastatic Solid Tumors
Interventions: TAK-981, Pembrolizumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 18
States / cities: Scottsdale, Arizona • Orange, California • Stanford, California + 15 more

Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer
Interventions: MEM-288 Intratumoral Injection, Nivolumab, Docetaxel; Biological · Drug
Lead sponsor: Memgen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 2
States / cities: Tampa, Florida • Durham, North Carolina

Conditions: Advanced or Metastatic Solid Tumors
Interventions: IPH4502; Drug
Lead sponsor: Innate Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Boston, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more

Conditions: Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma
Interventions: RAD001 + BEZ235; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 3
States / cities: Fayetteville, Arkansas • St Louis, Missouri • Charleston, South Carolina

Conditions: Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
Interventions: FX-909, Pembrolizumab (KEYTRUDA ®), KEYTRUDA ®( Pembrolizumab); Drug
Lead sponsor: Flare Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: San Francisco, California • New Haven, Connecticut • Miami, Florida + 7 more

Conditions: Solid Tumor, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung
Interventions: ATI-1123 (active drug = docetaxel); Drug
Lead sponsor: Azaya Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Dallas, Texas • San Antonio, Texas

Conditions: Advanced Solid Tumors, HNSCC, SCLC, NSCLC, TNBC - Triple-Negative Breast Cancer, CRC
Interventions: TUB-030; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 13
States / cities: New Haven, Connecticut • Miami, Florida • Boston, Massachusetts + 9 more

Conditions: Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions: AB-201, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Artiva Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors, Advanced or Metastatic KRAS-mutant Tumor
Interventions: WEF-001; Drug
Lead sponsor: Auricula Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Dallas, Texas • San Antonio, Texas

Conditions: Adult Solid Neoplasm, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions: Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Boston, Massachusetts • Nashville, Tennessee • Houston, Texas

Conditions: Medical Oncology
Interventions: BAY1161909, Paclitaxel; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 6
States / cities: Santa Monica, California • New Haven, Connecticut • Boston, Massachusetts + 3 more

Conditions: Solid Tumor
Interventions: PT0253, Chemotherapy Combination 1, Chemotherapy Combination 2, Chemotherapy Combination 3, Cetuximab; Drug
Lead sponsor: PAQ Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 4 more

Conditions: Cancers
Interventions: NM6603; Drug
Lead sponsor: NucMito Pharmaceuticals Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Detroit, Michigan • Cleveland, Ohio • Nashville, Tennessee + 1 more

Search by objective public record fields.

Clofarabine in Adult Patients With Advanced Solid Tumors

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

First-in-Human Study of MS201408-0005A as Single Agent and in Combinations

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

A Phase 1 Study of NM6603 in Advanced Solid Tumors